Biotechnology Research Innovation And Entrepreneurship Development (Bio-RIDE)(BIO-RIDE)

Bio-RIDE was sanctioned as a five-year outlay rather than an annual application cycle, so no opening or closing date exists for the scheme as a whole. Every date that matters belongs to an individual call, and it moves with the call.

The pattern worth planning around is visible in BIRAC's own call archive. Through 2025 the thematic calls under this scheme opened in a near-continuous sequence, on enzymes, smart proteins, carbon capture, climate-resilient agriculture, precision biotherapeutics, functional foods and futuristic marine research, each open for a matter of weeks rather than months, and several of them carried an extended last date. Missing one theme has usually meant waiting for the next rather than waiting a year, but the extension is a courtesy that has never been promised in advance.

Two separate doors exist, and an applicant is judged against only one of them.

For a company, LLP or industry applicant, the binding test is Indian control: the implementation plan for the biomanufacturing component requires an Indian legal entity with a minimum 51% stake owned and controlled by resident Indian citizens. Foreign investment that pushes resident holding below that line ends the application regardless of the science.

For an academic applicant, the qualification is institutional rather than financial. The Bio-AI call issued under the scheme opens submissions to institutions, universities, societies, trusts, NGOs and voluntary organisations recognised as a Scientific and Industrial Research Organisation, and adds a condition that catches people late in their careers: the Principal Investigator must have at least four years of employment remaining in the institution at the time of proposal submission, per the DBT-BIRAC Bio-AI call document.

The phrase "prior experience" in the eligibility list is not a self-declaration either. The implementation plan for the biomanufacturing component requires that details of the applicant's bio-services or biomanufacturing work be clearly specified inside the proposal itself, so the claim is assessed with the science.

myScheme carries no exclusion list for Bio-RIDE, but the call documents carry several, and they cut deeper than the eligibility bar does.

Land and building costs are not considered at all in the funded project cost, so a proposal built around real estate is asking for something the scheme does not buy. Support is also withheld from work that fails the biology test: the Bio-AI call states that proposals lacking significant biotech research questions and dwelling largely on computational programs or AI or ML methods will not be considered, and that the grant is not for establishing infrastructure or for applications of artificial intelligence aimed at screening, disseminating resources, healthcare or education. It is explicitly not for investigator-driven independent research either, which rules out a single scientist applying alone.

One more exclusion operates after the award. A grantee that fails to adhere to the terms of the grant agreement can be debarred from receiving any future grants from DBT or BIRAC, a condition the implementation plan requires to be written into the grant agreement and repeated in the call for proposals guidelines.

There is no renewal application in the sense a fellowship uses the word. A sanctioned project runs for its approved duration against defined objectives, milestones and deliverables, and the Bio-AI call fixes that duration at up to two years.

What continues, or does not, is decided by review. The implementation plan puts performance in the hands of the same two committees that selected the proposal, which may constitute a Project Monitoring Committee for onsite monitoring of the facility. A third-party evaluation of the component is carried out periodically, on a yearly basis or whenever required, and the report goes back to those committees. An applicant planning a multi-year build should read that as a recurring test rather than an automatic extension.

The ceilings differ by the kind of facility being proposed, and every one of them is an upper limit on budgetary support rather than a sum on offer. The Bio-AI research grant is the one the call document states the rule for outright: a maximum of Rs 25 crore, considered on merit and on the actual requirement of the proposal.

The ceiling is not the cheque for an industry applicant, because the cost-sharing rules attach to the same figure. A startup, SME or industry applicant seeking more than Rs 50 lakh brings a minimum 30% of the total project cost in cash, and that share is computed on a base from which land and construction have already been removed. Academic applicants sit on a different footing altogether, funded through grant-in-aid to mission mode projects under the Department's extramural research guidelines. The practical question for an industry proposal is therefore not whether the ask fits under the ceiling, but whether the matching contribution can be shown as cash on the balance sheet.

The published document list is the scheme's floor. The call documents ask for a thicker file, and most of it has to be produced by a chartered accountant or company secretary rather than by the science team.

A company or startup submits its incorporation certificate, a CA or CS certified shareholding pattern in BIRAC's format quoting a UDIN, audited financial details for the last three financial years, details of any in-house R&D facility or an incubation agreement with a recognised incubator, and copies of shareholders' passports where the Indian-holding test needs evidence. An LLP submits its registration certificate, the partnership deed, and a CA or CS certificate stating that at least half the partners are Indian citizens. A company or LLP that is recommended then has to declare that it is not in default of BIRAC or any other organisation and that no legal proceedings are running against it. Every proposal, academic or industrial, has to be forwarded by the executive head of the institution or company.

Nothing can be submitted to Bio-RIDE itself. DBT and BIRAC open the scheme through themed national calls, and each call carries its own scope, prescribed format and last date.

The route depends on who is applying. Academic institutions, research institutions and national laboratories submit through the Department's e-ProMIS portal at www.dbtepromis.nic.in in the prescribed format, forwarded by the executive head of the institution. Industry applicants, startups, DSIR-recognised non-profit organisations and industry-academia collaborations submit by logging in to the BIRAC website at www.birac.nic.in. Both routes are online only; hard copies are not part of the process. An organisation that has already registered on BIRAC for any of its schemes does not register again, per BIRAC's registration process page.

Some calls run in two steps. The Bio-AI call asked for problem statements and research solutions as a concept note first, with a full-length proposal sought only from shortlisted applicants, and the implementation plan notes that an Expression of Interest may be invited before full proposals with DBT's approval. Reading the call document before writing anything is the difference between a two-page note and a full technical and financial submission.

How to Check Where a Proposal Stands

Status is read from the applicant's own logged-in account on the BIRAC site. The applicant dashboard shown in BIRAC's proposal submission user guide carries a Status of Proposals panel with the stages a live application moves through, including Proposal Submitted, Under Consideration, Revision Required, Additional Upload Required, Ineligible or Not Recommended, and Approved or Recommended. A second panel tracks sanctioned projects through progress reports, completion, foreclosure and termination, which is where a funded grantee watches reporting obligations and project closure rather than the application itself. Technical problems with the academic route go to DBT's e-ProMIS application support desk, not to the programme officers.

Screening is done first, on eligibility alone, by a Preliminary Screening Committee. Proposals that survive it face a technical evaluation by the Selection Committee for Biofoundries and Biomanufacturing Hubs, which weighs expert comments and the applicant's presentation, and then a Financial Evaluation Committee that examines the co-funding, equity or royalty modalities. An Apex Committee makes the final recommendation, fixing objectives, milestones, duration, cost and the disbursement mechanism. Following the feasibility assessment, the implementation plan gives due weightage to the company bringing the best value to the Government, measured as the maximum percentage of cash contribution together with an upscaled technology.

The published outcomes give a sense of the competition. The first call for Bioenablers was issued in October 2024 and attracted 253 proposals; what emerged from it was India's first National Biofoundry Network of six biofoundries at institutions including ICGEB New Delhi, THSTI Faridabad and ACTREC Mumbai, together with 15 biomanufacturing platforms hosted largely at industry and industry-academia sites. The second call, issued in May 2025 and closed in July 2025, drew 213 proposals, 113 at DBT and 100 at BIRAC, of which 24, five at DBT and 19 at BIRAC, were recommended for the Apex Committee, according to DBT's biomanufacturing initiative page on the hubs.

Intellectual property arising from the Bio-AI programme is governed by the DBT Intellectual Property Guidelines of 2023, named in the call document rather than negotiated per project.

A funded facility also carries an access obligation. DBT notified a User Access Policy for the DBT and BIRAC biofoundries and biomanufacturing hubs established at academic institutions, research institutions and industry on 1 August 2025, and the stated intent is that these facilities serve outside academia, startups, SMEs and industry as well as their own in-house projects. A proposal written as though the equipment will only ever serve the host is arguing against the reason the component exists.

Programme queries for the biomanufacturing and bioenabler component go to the Department of Biotechnology directly, and the named officers are published rather than hidden behind a form. Dr. Sangita M Kasture, Scientist G, is the programme head and Dr. Kalaivani Ganesan, Scientist F, is the programme officer, reachable at k.ganesan@nic.in on 011-24365321, with the programme head's line listed as 011-24361035 on DBT's biomanufacturing initiative site, which also carries the Department's address at CGO Complex, Lodhi Road, New Delhi.

The Bio-AI call document adds three more addresses, and they are not interchangeable. Scheme questions on the bioenabler calls go to bio-enabler@dbt.nic.in, intellectual property and technology management questions go to akatiyar@birac.nic.in at BIRAC, and anything that is a technical fault in the online submission itself goes to the DBT application support team for e-ProMIS at epromise.dbt@nic.in or 011-24365136. The call document keeps the three apart, so a submission fault raised with a programme officer has not reached the team that can clear it.